AstraZeneca’s Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

All NewsJuly 14, 2025

AstraZeneca’s Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent